DB15342InvestigationalProtein Based Therapies
Panobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).
- Also known as
- AERUMAB · AERUMAB 11 · Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa · Human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa
- Code names
- KBPA-101
Resolves to
Compound
What you can answer from here — as of July 18, 2023
Which companies are running trials of Panobacumab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account